Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Equity

v3.8.0.1
Consolidated Statements of Equity - USD ($)
$ in Thousands
Total
EirGen Pharma Limited
BioReference Laboratories, Inc.
OPKO Health Europe
OPKO Renal
Transition Therapeutics, Inc.
Common Stock
Common Stock
EirGen Pharma Limited
Common Stock
BioReference Laboratories, Inc.
Common Stock
OPKO Renal
Common Stock
Transition Therapeutics, Inc.
Treasury
Treasury
OPKO Health Europe
Additional Paid-In Capital
Additional Paid-In Capital
EirGen Pharma Limited
Additional Paid-In Capital
BioReference Laboratories, Inc.
Additional Paid-In Capital
OPKO Health Europe
Additional Paid-In Capital
OPKO Renal
Additional Paid-In Capital
Transition Therapeutics, Inc.
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Noncontrolling Interests
Xenetic Biosciences, Inc.
Xenetic Biosciences, Inc.
Treasury
Xenetic Biosciences, Inc.
Additional Paid-In Capital
Beginning balance at Dec. 31, 2014 $ 835,741           $ 4,334         $ (4,051)   $ 1,529,096           $ (12,392) $ (674,843) $ (6,403)      
Beginning balance, shares (in shares) at Dec. 31, 2014             433,421,677         (1,245,367)                          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                  
Equity-based compensation expense 26,074                         26,074                      
Exercise of Common Stock options and warrants 25,920           $ 245             25,675                      
Exercise of Common Stock options, shares (in shares)             24,467,806                                    
Issuance of Common Stock in connection with acquisition 120,299 $ 33,596 $ 950,010   $ 20,112   $ 81 $ 24 $ 766 $ 12       120,218 $ 33,572 $ 949,244   $ 20,100              
Issuance of Common Stock in connection with acquisition (in shares)             8,118,062 2,420,487 76,566,147 1,194,337                              
Issuance of Treasury Stock in connection with Contingent Consideration       $ 1,812                 $ 406       $ 1,406                
Issuance of Treasury Stock in connection with Contingent Consideration (in shares)                         125,000                        
Net loss attributable to common shareholders (30,028)                                       (30,028)        
Deconsolidation of SciVac 6,403                                         6,403      
Other comprehensive loss (10,145)                                     (10,145)          
Ending balance at Dec. 31, 2015 1,979,794           $ 5,462         $ (3,645)   2,705,385           (22,537) (704,871) $ 0      
Ending balance, shares (in shares) at Dec. 31, 2015             546,188,516         (1,120,367)                          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                  
Equity-based compensation expense 42,693                         42,693                      
Exercise of Common Stock options and warrants 8,608           $ 33             8,575                      
Exercise of Common Stock options, shares (in shares)             3,292,753                                    
Issuance of Common Stock in connection with acquisition $ 583       $ 25,986 $ 58,530 $ 1     $ 26 $ 64     582       $ 25,960 $ 58,466            
Issuance of Common Stock in connection with acquisition (in shares)             51,235     2,611,648 6,431,899                            
Issuance of Treasury Stock in connection with Contingent Consideration       313                 $ 127       186                
Issuance of Treasury Stock in connection with Contingent Consideration (in shares)                         39,145                        
Issuance of Treasury Stock for investment in Xenetic                                             $ 4,856 $ 1,607 $ 3,249
Issuance of Treasury Stock for investment in Xenetic (in shares) 2,611,648                                             494,462  
Net loss attributable to common shareholders $ (25,083)                                       (25,083)        
Other comprehensive loss (4,472)                                     (4,472)          
Ending balance at Dec. 31, 2016 2,091,808           $ 5,586         $ (1,911)   2,845,096           (27,009) (729,954)        
Ending balance, shares (in shares) at Dec. 31, 2016             558,576,051         (586,760)                          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                  
Adoption of ASU 2016-09 31,665                                       31,665        
Equity-based compensation expense 28,307                         28,307                      
Exercise of Common Stock options and warrants $ 2,132           $ 14             2,118                      
Exercise of Common Stock options, shares (in shares) 1,298,704           1,447,694                                    
Reclassification of embedded derivatives to equity $ 13,551                         13,551                      
Issuance of Treasury Stock in connection with Contingent Consideration       $ 304                 $ 120       $ 184                
Issuance of Treasury Stock in connection with Contingent Consideration (in shares)                         36,853                        
Net loss attributable to common shareholders (308,870)                                       (308,870)        
Other comprehensive loss 26,481                                     26,481          
Ending balance at Dec. 31, 2017 $ 1,885,378           $ 5,600         $ (1,791)   $ 2,889,256           $ (528) $ (1,007,159)        
Ending balance, shares (in shares) at Dec. 31, 2017             560,023,745         (549,907)